← Back to Search

Chemotherapy

NANT Pancreatic Cancer Vaccine for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years old.
Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.

Eligible Conditions
  • Pancreatic Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.
Secondary outcome measures
Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months).
Duration of response
Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03.
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NANT Pancreatic Cancer VaccineExperimental Treatment12 Interventions
A combination of agents will be administered to subjects in this study: cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ETBX-011
2017
Completed Phase 2
~10
Paclitaxel
FDA approved
GI-4000
Not yet FDA approved
Inbakicept
Not yet FDA approved
Capecitabine
FDA approved
Fluorouracil
FDA approved
Leucovorin
FDA approved
Cyclophosphamide
FDA approved
Oxaliplatin
FDA approved
Bevacizumab
FDA approved
Avelumab
FDA approved

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
60 Previous Clinical Trials
5,100 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025